EA201891489A1 - Фармацевтическая композиция, содержащая аморфный леналидомид и антиоксидант - Google Patents

Фармацевтическая композиция, содержащая аморфный леналидомид и антиоксидант

Info

Publication number
EA201891489A1
EA201891489A1 EA201891489A EA201891489A EA201891489A1 EA 201891489 A1 EA201891489 A1 EA 201891489A1 EA 201891489 A EA201891489 A EA 201891489A EA 201891489 A EA201891489 A EA 201891489A EA 201891489 A1 EA201891489 A1 EA 201891489A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
antioxidant
composition containing
containing amorphous
amorphous lenalidomide
Prior art date
Application number
EA201891489A
Other languages
English (en)
Other versions
EA036205B1 (ru
Inventor
Марта Виванкос Мартинес
Лисардо Альварес Фернандес
Хосе Велада Кальсада
Original Assignee
Синтон Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Синтон Б.В. filed Critical Синтон Б.В.
Publication of EA201891489A1 publication Critical patent/EA201891489A1/ru
Publication of EA036205B1 publication Critical patent/EA036205B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к фармацевтической композиции, содержащей аморфный леналидомид или его фармацевтически приемлемую соль с синтетическим антиоксидантом и одним или несколькими фармацевтически приемлемыми эксципиентами. Изобретение также относится к способу получения таких композиций и применению указанной композиции в качестве лекарственного средства, особенно в лечении множественной миеломы и миелодиспластических синдромов.
EA201891489A 2015-12-22 2016-12-22 Фармацевтическая композиция, содержащая аморфный леналидомид и антиоксидант EA036205B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15202069 2015-12-22
PCT/EP2016/082318 WO2017109041A1 (en) 2015-12-22 2016-12-22 Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant

Publications (2)

Publication Number Publication Date
EA201891489A1 true EA201891489A1 (ru) 2018-11-30
EA036205B1 EA036205B1 (ru) 2020-10-14

Family

ID=55068830

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891489A EA036205B1 (ru) 2015-12-22 2016-12-22 Фармацевтическая композиция, содержащая аморфный леналидомид и антиоксидант

Country Status (7)

Country Link
US (2) US10328028B2 (ru)
EP (1) EP3393457A1 (ru)
AU (1) AU2016378482A1 (ru)
CL (1) CL2018001705A1 (ru)
EA (1) EA036205B1 (ru)
MX (1) MX2018007704A (ru)
WO (1) WO2017109041A1 (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3233059A1 (en) * 2014-12-19 2017-10-25 Synthon B.V. Pharmaceutical composition comprising amorphous lenalidomide
MA52119A (fr) 2015-10-19 2018-08-29 Ncyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
SG11201804152RA (en) 2015-11-19 2018-06-28 Incyte Corp Heterocyclic compounds as immunomodulators
ES2844374T3 (es) 2015-12-22 2021-07-22 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP3452476B1 (en) 2016-05-06 2021-12-15 Incyte Corporation Heterocyclic compounds as immunomodulators
TW201808902A (zh) 2016-05-26 2018-03-16 美商英塞特公司 作為免疫調節劑之雜環化合物
ES2927984T3 (es) 2016-06-20 2022-11-14 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
WO2018013693A1 (en) * 2016-07-13 2018-01-18 Celgene Corporation Solid dispersions and cocrystals comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione compositions and methods of use thereof
ES2930092T3 (es) 2016-07-14 2022-12-07 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
ES2941716T3 (es) 2016-08-29 2023-05-25 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP3558985B1 (en) 2016-12-22 2022-09-07 Incyte Corporation Benzooxazole derivatives as immunomodulators
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
MX2019007651A (es) 2016-12-22 2020-02-07 Incyte Corp Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de internalizacion de ligando 1 de muerte programada (pd-l1).
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
EP3700508A1 (en) 2017-10-26 2020-09-02 Synbias Pharma AG Lenalidomide immediate release formulations
WO2019138424A1 (en) * 2018-01-11 2019-07-18 Natco Pharma Limited Stable pharmaceutical compositions comprising lenalidomide
MX2020010321A (es) 2018-03-30 2021-01-08 Incyte Corp Compuestos heterociclicos como inmunomoduladores.
WO2019199136A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 붕해가 개선된 레날리도마이드의 경구용 정제 조성물
DK3790877T3 (da) 2018-05-11 2023-04-24 Incyte Corp Tetrahydro-imidazo[4,5-c]pyridinderivater som pd-l1-immunmodulatorer
EP4010342A1 (en) 2019-08-09 2022-06-15 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
CA3155852A1 (en) 2019-09-30 2021-04-08 Incyte Corporation PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS AS IMMUNOMODULATORS
MX2022005651A (es) 2019-11-11 2022-07-27 Incyte Corp Sales y formas cristalinas de un inhibidor de la proteina de muerte celular programada 1 (pd-1)/ligando de muerte celular programada 1 (pd-l1).
CN110664761A (zh) * 2019-11-18 2020-01-10 杭州百诚医药科技股份有限公司 一种来那度胺药物组合物及其制备方法
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor
JP2023548859A (ja) 2020-11-06 2023-11-21 インサイト・コーポレイション Ｐｄ－１／ｐｄ－ｌ１阻害剤ならびにその塩及び結晶形態を作製するためのプロセス
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
WO2022150561A1 (en) * 2021-01-08 2022-07-14 Starton Therapeutics, Inc. Stable solutions of immunomodulatory imide compounds for parenteral use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK9199A3 (en) 1996-07-24 1999-07-12 Celgene Corp 2,6-dioxopiperidines, pharmaceutical composition them containing and their use
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
EP2262768A4 (en) 2008-03-11 2011-03-23 Reddys Lab Ltd Dr PREPARATION OF LENALIDOMIDE
AU2009321374A1 (en) 2008-11-03 2010-06-03 Generics [Uk] Limited A crystalline form of lenalidomide and a process for its preparation
WO2010054833A1 (de) * 2008-11-14 2010-05-20 Ratiopharm Gmbh Intermediate und orale darreichungsformen enthaltend lenalidomid
ES2487215T3 (es) * 2009-03-02 2014-08-20 Generics [Uk] Limited Proceso mejorado
CN101537184B (zh) * 2009-04-30 2011-04-20 杭州中美华东制药有限公司 一种含水难溶高活性药物的组合物及其制备方法
US8877932B2 (en) 2010-03-08 2014-11-04 Natco Pharma Limited Anhydrous lenalidomide form-I
WO2013165973A1 (en) * 2012-04-30 2013-11-07 Senesco Technologies, Inc. Combination treatment of multiple myeloma
WO2014160686A1 (en) * 2013-03-26 2014-10-02 Celgene Corporation Solid forms comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereof
CN103705485B (zh) * 2013-12-31 2015-07-22 广州帝奇医药技术有限公司 一种用于治疗骨髓增生异常综合症的组合物及其制备方法

Also Published As

Publication number Publication date
CL2018001705A1 (es) 2018-08-10
WO2017109041A1 (en) 2017-06-29
EA036205B1 (ru) 2020-10-14
AU2016378482A1 (en) 2018-07-12
EP3393457A1 (en) 2018-10-31
MX2018007704A (es) 2018-11-09
US20190240157A1 (en) 2019-08-08
US20180256501A1 (en) 2018-09-13
US11007152B2 (en) 2021-05-18
US10328028B2 (en) 2019-06-25

Similar Documents

Publication Publication Date Title
EA201891489A1 (ru) Фармацевтическая композиция, содержащая аморфный леналидомид и антиоксидант
MX2021009673A (es) Moduladores de ror-gamma.
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201790528A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
EA201691516A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201591420A1 (ru) Гетероарильные соединения и их применение
EA201690753A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA202090683A3 (ru) Способы и композиции для лечения рака
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
CL2015002897A1 (es) Inhibidores de bace1
EA201692049A1 (ru) Гетероарилзамещенные гетероциклилсульфоны
EA201691670A1 (ru) Тетразолонзамещенные дигидропиридиноновые ингибиторы mgat2
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
EA201692043A1 (ru) Лекарственная форма иммунодепрессанта
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
EA201890364A1 (ru) СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ ИНГИБИРОВАНИЯ ROR-ГАММА-t
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы
EA201790253A1 (ru) Ингибиторы альдостеронсинтазы
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KG TM